Retinal vein occlusion (RVO) is a common blinding retinal vascular disease. Secondary macular edema, retinal ischemia, and neovascular complications can lead to severe visual impairment. The 2024 edition of Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China systematically elaborates on the etiology, classification, and diagnostic and therapeutic workflow of RVO, emphasizes the importance of whole-course management, clarifies the application principles of laser photocoagulation, and establishes anti-vascular endothelial growth factor (anti-VEGF) therapy as the first-line treatment. In recent years, the types of anti-VEGF drugs have continuously expanded, the administration schemes and clinical treatment experience have been continuously accumulated, and many new advancements have been made in the research on prognostic biomarkers, which have driven the drug treatment for RVO to enter a new stage of development. In view of this, it is of great clinical and practical significance to supplement the evidence and refine the strategies in the clinical intervention section of the 2024 edition of the consensus. Therefore, Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association, in collaboration with the expert group of Chinese expert consensus on clinical intervention pathway for retinal vein occlusion (2026 supplemented edition), after systematically reviewing the latest evidence-based medical data, referring to relevant international guidelines, and based on the current clinical practice situation in China, conducted in-depth discussions on six key clinical issues in the field of RVO drug therapy. They supplemented and updated the 2024 edition of Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China, and ultimately formed this consensus. This consensus aims to provide retinal specialists and other practitioners in ophthalmology with more advanced and personalized medical standardized guidance for RVO, ensuring treatment safety and efficacy for patients.